September 2024 decisions news release
The Scottish Medicines Consortium (SMC), which advises on newly licensed medicines for use by NHSScotland, has today (Monday, September 9) published advice on four medicines.
Dabrafenib (Finlee®) used in combination with another medicine, trametinib (Spexotras®) was accepted for treating children aged one year and older with a type of brain tumour called a glioma.
Ivosidenib (Tibsovo®) was accepted for treating adults with advanced cholangiocarcinoma, a cancer of the bile ducts in patients with a specific genetic mutation who have received at least one previous treatment.
Teclistamab (Tecvayli®) was accepted for treating adults with advanced myeloma who have had at least three previous treatments.
Elranatamab (Elrexfio®) was accepted on an interim basis for the treatment of adults with advanced myeloma who have received at least three previous treatments. The medicine will be available while further evidence is gathered. Following this, SMC will review the evidence and decide on routine availability in NHSScotland.
SMC Chair Dr Scott Muir said: “The committee is pleased to be able to accept these new medicines for use by NHSScotland.
“We heard powerful testimony from affected families about the devastating impact that the diagnosis of a glioma brain tumour has on children and their families. Dabrafenib together with trametinib may give children more time without their brain tumour growing and improve their quality of life.
“Ivosidenib offers the first personalised treatment for cholangiocarcinoma that can be taken at home, which we know will be welcomed by patients and their families.
“Teclistamab may be a useful additional treatment option for some patients with advanced myeloma who have already received at least three previous treatments.
“Elranatamab, for advanced myeloma, was accepted on an interim basis. The committee look forward to reviewing further clinical evidence, to ensure that this treatment offers useful clinical benefits to patients and good value for NHSScotland.”